The pattern-recognition receptor NOD1 promotes production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts
Arthritis & Rheumatism, 05/04/2012
Yokota K et al. – NOD–1 is strongly expressed in different cell types in the synovial tissue of patients with rheumatoid arthritis (RA). These results indicate that NOD–1, either alone or interacting with other inflammatory mediators, can play an important role in the chronic and destructive inflammation of the joints in RA.
Expression of NOD–1 was analyzed by immunohistochemistry in synovial tissue from RA patients, psoriatic arthritis patients, gout patients, and osteoarthritis (OA) patients.
RASFs and human monocyte–derived macrophages (HMDMs) were stimulated with L–alanyl–γ–D–glutamyl–meso–diaminopimelic acid, palmitoyl–3–cysteine–serine–lysine–4, poly(I–C), lipopolysaccharide, heat–inactivated bacteria, tumor necrosis factor α (TNF α), or interleukin–1 β (IL–1 β).
Expression levels of IL–6, CCL5, matrix metalloproteinases (MMPs), NODs, and TLRs were measured by real–time reverse transcription–polymerase chain reaction and/or enzyme–linked immunosorbent assay.
NOD–1 and NOD–2 were silenced with target–specific small interfering RNA.
Phosphorylation of IL–1 receptor–associated kinase 1 (IRAK–1) was measured by Western blotting.
Expression of NOD–1 protein was significantly increased in RA synovium compared to OA synovium.
The basal expression of NOD–1 was similar in RASFs, OASFs, healthy control peripheral blood mononuclear cells, and healthy control HMDMs.
Stimulation of RASFs with TLR–3 up–regulated the expression of NOD–1.
Expression of IL–6, CCL5, MMPs, TLR–2, and NOD–2 was significantly up–regulated in RASFs by stimulation with the NOD–1 ligand.
A synergistic effect on IL–6 production was observed in cells stimulated with NOD–1 and TLR–2 ligands or NOD–1 and TLR–4 ligands.
Silencing of NOD–1, but not NOD–2, decreased the levels of IL–6 in RASFs after stimulation with TLR–2 and IL–1β, and blocked the phosphorylation of IRAK–1.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.